Brief: Bayer AG - Kerendia Approved In EU For New Indication
30/03/2026 07:32
March 30 (Reuters) - BAYER AG BAYGn.DE: BAYER AG - KERENDIA APPROVED IN EU FOR NEW INDICATION IN ADULT PATIENTS WITH HEART FAILURE WITH LVEF ≥40% Further company coverage: [BAYGn.DE] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)